Core Insights - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [2] Company Overview - Upstream Bio is developing verekitug, the only known antagonist in clinical development targeting the receptor for thymic stromal lymphopoietin (TSLP), which is a key driver of inflammatory responses [2] - The company has advanced verekitug into separate Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD) [2] - Upstream Bio aims to address significant unmet needs for patients who are underserved by current standard care [2] Upcoming Events - Rand Sutherland, CEO of Upstream Bio, will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 4:30 p.m. ET [3] - The company will also be present at the 8th Annual Evercore Healthcare Conference on December 4, 2025, at 10:25 a.m. ET [3] - Live webcasts of these presentations will be available on Upstream Bio's website, with replays posted afterward [1][3]
Upstream Bio to Participate in Upcoming December Investor Conferences